| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/12/2010 | US20100203050 Erythropoietin fusion protein |
| 08/12/2010 | US20100203049 Interleukin-10 Antibodies |
| 08/12/2010 | US20100203048 Methods of using corticotropin-releasing factor for the use of the treatment of cancer |
| 08/12/2010 | US20100203047 Novel Compositions And Methods For Stimulating Erythropoiesis In A Mammal |
| 08/12/2010 | US20100203046 Fc gamma receptor-binding polypeptide variants and methods related thereto |
| 08/12/2010 | US20100203045 EPH RECEPTOR Fc VARIANTS WITH ENHANCED ANTIBODY DEPENDENT CELL-MEDIATED CYTOTOXICITY ACTIVITY |
| 08/12/2010 | US20100203044 Dr6 antagonists and uses thereof in treating neurological disorders |
| 08/12/2010 | US20100203043 Treatment and diagnosis of metastatic prostate cancer with inhibitors of epidermal growth factor receptor (egfr) |
| 08/12/2010 | US20100203042 Recombinant anti-vla4 antibody molecules |
| 08/12/2010 | US20100203041 Antibodies to egfl7 and methods for their use |
| 08/12/2010 | US20100203040 Genetic Products Which are Differentially Expressed in Tumors and Use Thereof |
| 08/12/2010 | US20100203039 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
| 08/12/2010 | US20100203038 Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual |
| 08/12/2010 | US20100203037 identifying a Glucose-dependent Insulinotropic Peptide (GIP) secretagogue; G protein-coupled receptor (GPCR); useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis |
| 08/12/2010 | US20100203036 Targets for tumor growth inhibition |
| 08/12/2010 | US20100203035 B7-h3 in cancer |
| 08/12/2010 | US20100203034 Methods for the treatment and prevention of diseases of biological conduits |
| 08/12/2010 | US20100203011 Mammalian Cytokines; Related Reagents and Methods |
| 08/12/2010 | US20100203010 Modulation of tumor microenvironment |
| 08/12/2010 | US20100203009 Pathway for Th-17 Cell Development and Methods Utilizing Same |
| 08/12/2010 | US20100203007 Novel benzodiazepine derivatives |
| 08/12/2010 | US20100202968 Method of Providing Disease-Specific Binding Molecules and Targets |
| 08/12/2010 | US20100202963 Therapies for hematologic malignancies |
| 08/12/2010 | US20100202962 Cripto blocking antibodies and uses thereof |
| 08/12/2010 | US20100202961 Immunological reagents for therapeutic use, in radioimmunotherapy (RAIT), and diagnostic use, in radioimmunodetection (RAID) and magnetic resonance imaging; conjugated drug as antiinflammatory, or anticarcinogenic agents; drug targets; tissue-targeted therapy |
| 08/12/2010 | CA2751571A1 Sam-6 variants, target and methods of use |
| 08/12/2010 | CA2751500A1 Grass peptides for vaccine |
| 08/12/2010 | CA2751445A1 Truncated cystine-knot proteins |
| 08/12/2010 | CA2751438A1 Methods and compositions for treatment of neovascularization |
| 08/12/2010 | CA2751433A1 Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection |
| 08/12/2010 | CA2750705A1 Contiguous overlapping peptides for treatment of birch pollen allergy |
| 08/12/2010 | CA2750067A1 Splitting gp41 |
| 08/12/2010 | CA2750058A1 Novel gp41 antigens |
| 08/12/2010 | CA2750038A1 Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors |
| 08/11/2010 | EP2216409A1 Albumin fusion proteins |
| 08/11/2010 | EP2216404A1 Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
| 08/11/2010 | EP2216400A1 Method for manufacturing an active component of a medicine or diagnosis agent in MDCJ cell suspension culture |
| 08/11/2010 | EP2216344A1 Diagnosis and treatment of cancer using anti-gpr49 antibody |
| 08/11/2010 | EP2216343A1 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof |
| 08/11/2010 | EP2216342A1 Anti-CD19 antibodies |
| 08/11/2010 | EP2216046A2 Anti-glypican 3 antibody |
| 08/11/2010 | EP2216045A1 Engineered pertactin variants for vaccine use |
| 08/11/2010 | EP2216044A1 Capsular polysaccharide solubilisation and combination vaccines |
| 08/11/2010 | EP2216041A1 Method for induction of cytotoxic t-cell, cytotoxic t-cell inducer, and pharmaceutical composition and vaccine each comprising the inducer |
| 08/11/2010 | EP2216033A2 Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues |
| 08/11/2010 | EP2216028A2 Immunostimulation by chemically modified RNA |
| 08/11/2010 | EP2216027A2 Chemically modified RNA for immunpstimulation |
| 08/11/2010 | EP2215474A2 Antibody therapy for modulating function of intestinal receptors |
| 08/11/2010 | EP2215220A1 Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28 |
| 08/11/2010 | EP2215122A1 Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof |
| 08/11/2010 | EP2215121A1 Anti-mesothelin antibodies and uses therefor |
| 08/11/2010 | EP2215120A2 Humanized antibody molecules specific for il-31 |
| 08/11/2010 | EP2215118A1 Antibodies to gdf8 as uses thereof |
| 08/11/2010 | EP2214715A1 Method of delivering an anti-cancer agent to a cell |
| 08/11/2010 | EP2214711A2 Anti-rsv g protein antibodies |
| 08/11/2010 | EP2214710A1 Human anti-vegf polyclonal antibodies and uses thereof |
| 08/11/2010 | EP2214708A2 Vectors, host cells, and methods of production and uses |
| 08/11/2010 | EP2214706A1 Use of trkb antibodies for the treatment of respiratory disorders |
| 08/11/2010 | EP2214705A2 A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant |
| 08/11/2010 | EP2214704A2 Allergen desensitization method |
| 08/11/2010 | EP2214702A2 Mycoplasma bovis vaccine and methods of use thereof |
| 08/11/2010 | EP2214701A2 Compositions and methods of enhancinc immune responses to eimeria |
| 08/11/2010 | EP2214700A1 Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses |
| 08/11/2010 | EP2214691A1 Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| 08/11/2010 | EP2214656A1 Compositions and methods for enhancing immune response |
| 08/11/2010 | EP1984522B1 Methods of increasing lymphatic function |
| 08/11/2010 | EP1827492B1 Antibodies directed to gpnmb and uses thereof |
| 08/11/2010 | EP1716178B1 Less immunogenic binding molecules |
| 08/11/2010 | EP1680141B1 Methods of therapy for solid tumors expressing the cd40 cell-surface antigen |
| 08/11/2010 | EP1515750B1 Combinations comprising epothilones and pharmaceutical uses thereof |
| 08/11/2010 | EP1489170B1 Transporter selectively transporting sulfate conjugate and its gene |
| 08/11/2010 | EP1483294B1 Internalizing anti-cd74 antibodies and methods of use |
| 08/11/2010 | EP1303300B1 Compositions and methods for treatment of candidiasis |
| 08/11/2010 | EP1135415B1 Humanized antibodies to gamma-interferon |
| 08/11/2010 | EP1007625B1 Immunity enhancing lactic acid bacteria |
| 08/11/2010 | EP0988063B2 Process for reducing the concentration of viral and molecular pathogens in a biological material |
| 08/11/2010 | CN101802198A immunogenic polypeptides and monoclonal antibodies |
| 08/11/2010 | CN101802197A Single-chain FC (ScFc) regions, binding polypeptides comprising same, and methods related thereto |
| 08/11/2010 | CN101802179A Two-component genome flavivirus and uses thereof |
| 08/11/2010 | CN101802013A Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
| 08/11/2010 | CN101802012A Anti-CD79b antibodies and immunoconjugates and methods of use |
| 08/11/2010 | CN101802011A mdl-1 uses |
| 08/11/2010 | CN101802008A Human C-FMS antigen binding proteins |
| 08/11/2010 | CN101802007A Monoclonal anti-beta amyloid antibody |
| 08/11/2010 | CN101802002A Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| 08/11/2010 | CN101801462A Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders |
| 08/11/2010 | CN101801417A Macrophage transfection method |
| 08/11/2010 | CN101801413A Combination therapies employing GITR binding molecules |
| 08/11/2010 | CN101801412A Varicella zoster virus-virus like particles (VLPS) and antigens |
| 08/11/2010 | CN101801411A Chimeric varicella zoster virus-virus like particles |
| 08/11/2010 | CN101801410A compositions and methods for preventing influenza infection in canines, felines and equines |
| 08/11/2010 | CN101801409A compositions comprising pneumococcal antigens |
| 08/11/2010 | CN101801408A electroporation of mycobacterium and overexpression of antigens in mycobacteria |
| 08/11/2010 | CN101801407A Inhibitors of receptor tyrosine kinases and methods of use thereof |
| 08/11/2010 | CN101801372A Combinations of SAP depleting agents and anti-SAP antibodies |
| 08/11/2010 | CN101801344A Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery |
| 08/11/2010 | CN101801343A antigen-adjuvant compositions and methods |
| 08/11/2010 | CN101799476A Reagent box for sieving autoantibody for tsh receptor |
| 08/11/2010 | CN101798600A Application of SERPINE2 gene |
| 08/11/2010 | CN101798565A Bacillus anthracis capable of showing PA20 protein on surface of spore and application thereof |